Cyclophosphamide vs rituximab induction therapy for ANCA-associated vasculitis. A systematic review and meta-analysis of 12-month mortality. (PubMed, Semin Arthritis Rheum) - Sep 22, 2026 - "Overall, there was a statistically significant difference favouring rituximab in 12-month mortality rates after cyclophosphamide or rituximab induction treatment for AAV. Subgroup sensitivity analysis considering study populations consistently supported this result although only treatment for GPA and baseline BVAS <17 reached statistical significance. Further direct studies between cyclophosphamide and rituximab induction are required."
Journal • Retrospective data • ANCA Vasculitis • Vasculitis
|
|
Caroline Allan; Christopher Frampton; Gursimran Kaur; Laila Girgis; Lisa K Stamp; Richard Day
|